4//SEC Filing
MANIAN BALA S 4
Accession 0001062993-24-010182
CIK 0001205922other
Filed
May 13, 8:00 PM ET
Accepted
May 14, 4:33 PM ET
Size
14.8 KB
Accession
0001062993-24-010182
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
MANIAN BALA S
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-05-10+10,108→ 10,108 totalExercise: $5.75From: 2025-05-10→ Common Stock (10,108 underlying) - Award
Stock Option (Right to Buy)
2024-05-10$3.96/sh+2,685$10,633→ 2,685 totalExercise: $5.75From: 2024-05-10Exp: 2034-05-10→ Common Stock (2,685 underlying)
Holdings
- 36
Stock Option (Right to Buy)
Exercise: $1633.80From: 2020-05-15→ Common Stock (36 underlying) - 74
Stock Option (Right to Buy)
Exercise: $829.50From: 2021-05-14→ Common Stock (74 underlying) - 136
Stock Option (Right to Buy)
Exercise: $451.50From: 2022-05-11→ Common Stock (136 underlying) - 253
Stock Option (Right to Buy)
Exercise: $235.20From: 2023-05-12→ Common Stock (253 underlying) - 684
Stock Option (Right to Buy)
Exercise: $86.10From: 2024-05-11→ Common Stock (684 underlying)
Footnotes (7)
- [F1]This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
- [F2]This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
- [F3]This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
- [F4]This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
- [F5]This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
- [F6]Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
- [F7]This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
Issuer
VACCINEX, INC.
CIK 0001205922
Entity typeother
Related Parties
1- filerCIK 0000941871
Filing Metadata
- Form type
- 4
- Filed
- May 13, 8:00 PM ET
- Accepted
- May 14, 4:33 PM ET
- Size
- 14.8 KB